La cadena de opciones muestra datos clave de las opciones de acciones de Abpro Hldgs a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para Abpro Hldgs..

Abpro Hldgs (NASDAQ:ABP) Bolsa, Cadena de Opciones

Abpro Hldgs

Abpro Holdings Inc is a biotechnology company dedicated to developing next-generation antibody therapeutics with the goal of improving the lives of patients with severe and life-threatening diseases. It is focused on novel antibody constructs for immuno-oncology and ophthalmology. By leveraging its proprietary DiversImmune and MultiMabTM antibody discovery and engineering platforms. The company is developing a pipeline of next-generation antibodies, both independently and through collaborations with pharmaceutical and research institutions.

Quantum,Computing,Concept,,Quantum,Mechanics,,Advanced,Technology,,Artificial,Intelligence,And

AMAT

BFRI

CISO

CLIK

DOCS

GLOB

HCTI

IXHL

KLRS

LGPS

ORGN

PTIX

QUBT

SATL

SPCE

TSSI

TVTX

Descubre las acciones que destacan en el premercado de EE. UU.: Quantum Computing sube tras superar expectativas, mientras otras caen.

Acciones de Quantum Computing (QUBT) se disparan un 12%; aquí están 20 acciones que se mueven en premercado

Stock,Market,Graph,Trading,Analysis,Investment,Financial,,Stock,Exchange,Financial

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

ABSI

ALLT

ALUR

ASNS

AXDX

DBVT

DEVS

FNGR

GRAL

LRHC

LUCY

PLRZ

UBER

WBUY

XHLD

XTKG

Las acciones de Everus Construction Group suben un 14,7 % tras superar expectativas de ganancias y ventas en el primer trimestre.

Acciones de Everus Construction (ECG) se disparan un 15%; Aquí están 20 acciones que se mueven en premercado

Providing a diverse range of perspectives from bullish to bearish, 8 analysts have published ratings on Gates Industrial Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GTES#NYSE">GTES</a>) in the last three months.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">5</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $27.0, a high estimate of $30.00, and a low estimate of $23.00. This upward trend is apparent, with the current average reflecting a 13.07% increase from the previous average price target of $23.88.
<img src="https://www.benzinga.com/files/images/story/2025/1753995638_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
The analysis of recent analyst actions sheds light on the perception of Gates Industrial Corp by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Deane Dray</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$29.00</td>
<td>$28.00</td>
</tr>
<tr>
<td>Jeffrey Hammond</td>
<td>Keybanc</td>
<td>Raises</td>
<td>Overweight</td>
<td>$30.00</td>
<td>$26.00</td>
</tr>
<tr>
<td>Damian Karas</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$30.00</td>
<td>$27.00</td>
</tr>
<tr>
<td>Andrew Kaplowitz</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$29.00</td>
<td>$22.00</td>
</tr>
<tr>
<td>Julian Mitchell</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$26.00</td>
<td>$23.00</td>
</tr>
<tr>
<td>Jeffrey Hammond</td>
<td>Keybanc</td>
<td>Raises</td>
<td>Overweight</td>
<td>$26.00</td>
<td>$23.00</td>
</tr>
<tr>
<td>Jerry Revich</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Neutral</td>
<td>$23.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>Julian Mitchell</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$23.00</td>
<td>$22.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Gates Industrial Corp. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Gates Industrial Corp compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for Gates Industrial Corp's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Gates Industrial Corp's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/GTES/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Gates Industrial Corp analyst ratings.</a>
<h2>Unveiling the Story Behind Gates Industrial Corp</h2>
Gates Industrial Corp PLC is a manufacturer of engineered power transmission and fluid power solutions. The company has two operating segments; Power Transmission and Fluid Power segments. The Power Transmission solutions convey power and control motion. It is used in applications in which belts, chains, cables, geared transmissions, or direct drives transfer power from an engine or motor to another part or system. The Fluid power solutions are used in applications in which hoses and rigid tubing assemblies either transfer power hydraulically or convey fluids, gases, or granular materials from one location to another. The company generates key revenue from the Power Transmission segment. Company operates in USA, United Kingdom, Luxembourg, EMEA, with majority revenue from USA.
<h3>Gates Industrial Corp's Financial Performance</h3>
Market Capitalization: Exceeding industry standards, the company's market capitalization places it above industry average in size relative to peers. This emphasizes its significant scale and robust market position.
Decline in Revenue: Over the 3M period, Gates Industrial Corp faced challenges, resulting in a decline of approximately -1.74% in revenue growth as of 31 March, 2025. This signifies a reduction in the company's top-line earnings. When compared to others in the Industrials sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Gates Industrial Corp's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of 7.31%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Gates Industrial Corp's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of 2.02%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): Gates Industrial Corp's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of 0.91%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: Gates Industrial Corp's debt-to-equity ratio surpasses industry norms, standing at 0.8. This suggests the company carries a substantial amount of debt, posing potential financial challenges.
<h2>Analyst Ratings: Simplified</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

GTES

Forecasting The Future: 8 Analyst Projections For Gates Industrial Corp

WIIM

Cooper-Standard Holdings shares are trading higher after the company reported better-than-expected Q2 financial results and issued FY25 sales guidance above estimates.

8 analysts have shared their evaluations of F5 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FFIV#NASDAQ">FFIV</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">7</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated F5 and provided 12-month price targets. The average target is $321.62, accompanied by a high estimate of $355.00 and a low estimate of $304.00. Witnessing a positive shift, the current average has risen by 9.44% from the previous average price target of $293.88.
<img src="https://www.benzinga.com/files/images/story/2025/1753995630_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive F5. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tim Long</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$321.00</td>
<td>$274.00</td>
</tr>
<tr>
<td>Matthew Hedberg</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$326.00</td>
<td>$314.00</td>
</tr>
<tr>
<td>Meta Marshall</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$312.00</td>
<td>$305.00</td>
</tr>
<tr>
<td>James Fish</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Neutral</td>
<td>$355.00</td>
<td>$304.00</td>
</tr>
<tr>
<td>Ryan Koontz</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$345.00</td>
<td>$320.00</td>
</tr>
<tr>
<td>Meta Marshall</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$305.00</td>
<td>$280.00</td>
</tr>
<tr>
<td>Samik Chatterjee</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Neutral</td>
<td>$305.00</td>
<td>$285.00</td>
</tr>
<tr>
<td>James Fish</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Neutral</td>
<td>$304.00</td>
<td>$269.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to F5. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of F5 compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of F5's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
To gain a panoramic view of F5's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/FFIV/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on F5 analyst ratings.</a>
<h2>Unveiling the Story Behind F5</h2>
F5 is a market leader in the application delivery controller market. The company sells products for security, application performance, and automation. Its three customer verticals are enterprises, service providers, and government entities. Revenue is evenly split between its services business and products business with revenue trending toward products due to software adoption. The Seattle-based firm was incorporated in 1996, and went public in 1999.
<h3>F5: Delving into Financials</h3>
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: Over the 3M period, F5 showcased positive performance, achieving a revenue growth rate of 7.3% as of 31 March, 2025. This reflects a substantial increase in the company's top-line earnings. When compared to others in the Information Technology sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: F5's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 19.91% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 4.44%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): F5's ROA excels beyond industry benchmarks, reaching 2.47%. This signifies efficient management of assets and strong financial health.
Debt Management: With a below-average debt-to-equity ratio of 0.08, F5 adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

FFIV

What 8 Analyst Ratings Have To Say About F5

6 analysts have expressed a variety of opinions on Nurix Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NRIX#NASDAQ">NRIX</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $27.67, a high estimate of $34.00, and a low estimate of $16.00. Experiencing a 6.2% decline, the current average is now lower than the previous average price target of $29.50. 
<img src="https://www.benzinga.com/files/images/story/2025/1753995622_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Nurix Therapeutics. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Matthew Biegler</td>
<td>Oppenheimer</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$30.00</td>
<td>$32.00</td>
</tr>
<tr>
<td>Terence Flynn</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$16.00</td>
<td>$17.00</td>
</tr>
<tr>
<td>Robert Burns</td>
<td>HC Wainwright &amp; Co.</td>
<td>Lowers</td>
<td>Buy</td>
<td>$34.00</td>
<td>$36.00</td>
</tr>
<tr>
<td>David Dai</td>
<td>UBS</td>
<td>Lowers</td>
<td>Buy</td>
<td>$26.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>Matthew Biegler</td>
<td>Oppenheimer</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$30.00</td>
<td>$32.00</td>
</tr>
<tr>
<td>Sudan Loganathan</td>
<td>Stephens &amp; Co.</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$30.00</td>
<td>$30.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Nurix Therapeutics. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Nurix Therapeutics compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of Nurix Therapeutics's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Nurix Therapeutics's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/NRIX/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Nurix Therapeutics analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>About Nurix Therapeutics</h2>
Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies.
<h3>Financial Milestones: Nurix Therapeutics's Journey</h3>
Market Capitalization Analysis: Above industry benchmarks, the company's market capitalization emphasizes a noteworthy size, indicative of a strong market presence.
Revenue Growth: Nurix Therapeutics displayed positive results in 3M. As of 31 May, 2025, the company achieved a solid revenue growth rate of approximately 264.34%. This indicates a notable increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of -98.66%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Nurix Therapeutics's ROE stands out, surpassing industry averages. With an impressive ROE of -9.36%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of -7.2%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.12.
<h2>The Basics of Analyst Ratings</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

NRIX

6 Analysts Assess Nurix Therapeutics: What You Need To Know

In the current session, the stock is trading at $41.47, after a 4.35% spike. Over the past month, Vontier Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VNT#NYSE">VNT</a>) stock increased by 7.88%, and in the past year, by 25.59%. With performance like this, long-term shareholders are optimistic but others are more likely to look into the price-to-earnings ratio to see if the stock might be overvalued.

<img src="https://www.benzinga.com/files/images/story/2025/1753995619_0.png" alt="Past Year Chart" />

<h3>A Look at Vontier P/E Relative to Its Competitors</h3>
The P/E ratio is used by long-term shareholders to assess the company's market performance against aggregate market data, historical earnings, and the industry at large. A lower P/E could indicate that shareholders do not expect the stock to perform better in the future or it could mean that the company is undervalued. 
Vontier has a lower P/E than the aggregate P/E of 41.38 of the Electronic Equipment, Instruments &amp; Components industry. Ideally, one might believe that the stock might perform worse than its peers, but it's also probable that the stock is undervalued. 

<img src="https://www.benzinga.com/files/images/story/2025/1753995619_1.png" alt="Guage" />

In summary, while the price-to-earnings ratio is a valuable tool for investors to evaluate a company's market performance, it should be used with caution. A low P/E ratio can be an indication of undervaluation, but it can also suggest weak growth prospects or financial instability. Moreover, the P/E ratio is just one of many metrics that investors should consider when making investment decisions, and it should be evaluated alongside other financial ratios, industry trends, and qualitative factors. By taking a comprehensive approach to analyzing a company's financial health, investors can make well-informed decisions that are more likely to lead to successful outcomes.

Intraday Update

P/E Ratio Insights for Vontier

Intuit (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTU#NASDAQ">INTU</a>) has outperformed the market over the past 20 years by 10.64% on an annualized basis producing an average annual return of 19.15%. Currently, Intuit has a market capitalization of $219.08 billion. 
Buying $100 In INTU: If an investor had bought $100 of INTU stock 20 years ago, it would be worth $3,336.72 today based on a price of $785.40 for INTU at the time of writing.
<h3>Intuit's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1753995615_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

INTU

$100 Invested In Intuit 20 Years Ago Would Be Worth This Much Today

Dundee Precious Metals (TSX:<a class="ticker" href="https://www.benzinga.com/stock/DPM#TSX">DPM</a>) reported quarterly earnings of $0.52 per share which beat the analyst consensus estimate of $0.49 by 6.12 percent. This is a 33.33 percent increase over earnings of $0.39 per share from the same period last year. The company reported quarterly sales of $186.487 million which beat the analyst consensus estimate of $178.000 million by 4.77 percent. This is a 18.90 percent increase over sales of $156.838 million the same period last year.

Earnings

Earnings Beats

TSX:DPM

Dundee Precious Metals Q2 Adj. EPS $0.52 Beats $0.49 Estimate, Sales $186.487M Beat $178.000M Estimate

WEAV

Weave Communications shares are trading higher after the company reported better-than-expected Q2 financial results.

BYFC

Broadway Financial Q2 EPS $(0.02) Down From $0.03 YoY, Sales $8.110M Down From $8.191M YoY

BOOT

Boot Barn Holdings shares are trading higher after the company reported better-than-expected Q1 financial results, issued Q2 guidance above estimates, and raised its FY26 guidance.

ENVX

Enovix shares are trading lower after the company released its Q2 financial results.

Guidance

ICFI

ICF International Raises FY2025 GAAP EPS Guidance from $5.24-$5.82 to $5.82 vs $5.27 Est

ICF International Raises FY2025 Adj EPS Guidance from $6.71-$7.45 to $7.45 vs $6.89 Est; FY2025  Revenue expected to be more than $1.818B vs $1.912B Est

Eastman Chemical shares are trading lower after the company reported worse-than-expected Q2 financial results and issued Q3 adjusted EPS guidance below estimates.

Riot Platforms (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIOT#NASDAQ">RIOT</a>) reported quarterly earnings of $0.57 per share which beat the analyst consensus estimate of $(0.10) by 658.82 percent. This is a 278.12 percent increase over losses of $(0.32) per share from the same period last year. The company reported quarterly sales of $152.988 million which beat the analyst consensus estimate of $147.650 million by 3.62 percent. This is a 118.50 percent increase over sales of $70.018 million the same period last year.

RIOT

Riot Platforms Q2 EPS $0.57 Beats $(0.10) Estimate, Sales $152.988M Beat $147.650M Estimate

Roku (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROKU#NASDAQ">ROKU</a>) raises FY2025 sales outlook from $4.550 billion to $4.650 billion vs $4.555 billion estimate.

ROKU

CORRECTION: Roku Raises FY2025 Sales Guidance from $4.550B to $4.650B vs $4.555B Est

Apple Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) reported third-quarter financial results after the market close on Thursday. Here&#8217;s a look at the key details from the <a href="https://www.benzinga.com/pressreleases/25/07/b46775533/apple-reports-third-quarter-results">tech giant&#8217;s report</a>.
Q3 Earnings: Apple reported fiscal third-quarter revenue of $94 billion, beating analyst&nbsp;<a href="https://www.benzinga.com/quote/AAPL/earnings" target="_blank" rel="noreferrer noopener">estimates</a>&nbsp;of $89.04 billion. The iPhone maker reported third-quarter earnings of $1.57 per share, beating analyst estimates of $1.42 per share, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Total revenue was up 10% year-over-year, and earnings per share climbed 12% year-over-year. Americas sales totaled $41.2 billion in the quarter, Europe sales came in at $24.01 billion, Greater China sales were approximately $15.37 billion, Japan sales totaled $5.78 billion and the rest of Asia Pacific sales were $7.67 billion.
Apple noted that its active installed base of devices once again reached new all-time highs across all products and geographic segments. The company attributed the growth to high levels of customer satisfaction and loyalty.
Products revenue came in at $66.61 billion, up from $61.56 billion year-over-year. Services revenue totaled $27.42 billion, up from $24.21 billion year-over-year. Here's a breakdown of product sales by category:
<ul class="wp-block-list">
<li>iPhone: $44.58 billion, versus $39.3 billion last year</li>
<li>Mac: $8.05 billion, versus $7.01 billion last year</li>
<li>iPad: $6.58 billion, versus $7.16 billion last year</li>
<li>Wearables, Home and Accessories: $7.4 billion, versus $8.1 billion last year</li>
</ul>
&#8220;Today Apple is proud to report a June quarter revenue record with double-digit growth in iPhone, Mac and Services and growth around the world, in every geographic segment,&#8221; said&nbsp;Tim Cook, CEO of Apple.
&#8220;At WWDC25, we were excited to introduce a beautiful new software design that extends across all of our platforms, and we announced even more great Apple Intelligence features.&#8221;
Apple ended the quarter with $36.27 billion in cash and cash equivalents. The company&#8217;s board declared a quarterly cash dividend of&nbsp;26 cents&nbsp;per share, payable on Aug. 14 to shareholders of record as of Aug. 11.
Apple has an earnings call scheduled for 5 p.m. ET. A link to the third-quarter call can be found below. The company tends to provide commentary on the call on how it generally expects its different product lines to perform over the coming months.
AAPL Price Action: <a href="http://benzinga.com/quote/aapl" target="_blank" rel="noreferrer noopener">Apple shares</a> were up 3% in after-hours, trading at $213.79 at the time of publication Thursday, according to <a href="http://pro.benzinga.com/" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/large-cap/25/07/46766944/stock-market-outlook-sp500-august-seasonality-magnificent-seven">Stock Market Outlook: July&#8217;s Highs Mask A Dangerous August Twist</a></li>
</ul>
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/tech/25/07/46680504/apple-faces-18-month-deadline-to-deliver-on-ai-says-analyst">Apple Faces 18-Month Deadline To Deliver On AI, Says Analyst</a></li>
</ul>
Photo: hanohiki/Shutterstock.com
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="Apple Earnings Call Q3 2025 &#x7C; $AAPL &#x7C; &#x1f534; WATCH LIVE" width="500" height="281" src="https://www.youtube.com/embed/DgePMQwv-m8?feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>

Tech

AAPL

Apple Q3 Earnings: Revenue, EPS Smash Estimates As iPhone Sales Jump, Active Installed Base Reaches New Highs

Management

Wells Fargo Appoints Charlie Scharf As Chairman

On July 24, 2025, Future FinTech Group Inc. (the "Company") entered into a securities purchase agreement (the "Equity SPA") with certain institutional and individual investors (each, a "Purchaser"), pursuant to which the Company agreed to issue and sell, and the Purchasers agreed to purchase, up to an aggregate of 15,000,000 shares of the Company's common stock, par value $0.001 per share (the "Common Stock"), at a purchase price of $2.00 per share. No significant shareholder or officer of the Company participated in the First Transaction. The initial closing is capped at no more than 19.9% of the Company's outstanding Common Stock as of the closing date (the "19.9% Limit") and with the issuance of the remaining shares of Common Stock pursuant to the Equity SPA subject to shareholder approval as explained below.
 &nbsp;

General

FTFT

Future FinTech Group Entered Securities Purchase Agreement With Institutional And Individual Investors Up To 15M Shares At $2/Share

Mercer Intl (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MERC#NASDAQ">MERC</a>) reported quarterly losses of $(1.29) per share which missed the analyst consensus estimate of $(0.87) by 48.28 percent. This is a 27.72 percent decrease over losses of $(1.01) per share from the same period last year. The company reported quarterly sales of $453.52 million which missed the analyst consensus estimate of $514.00 million by 11.77 percent. This is a 9.18 percent decrease over sales of $499.38 million the same period last year.

Earnings Misses

MERC

Mercer Intl Q2 EPS $(1.29) Misses $(0.87) Estimate, Sales $453.52M Miss $514.00M Estimate

Health Care

Financing

Press Releases

Abpro Holdings Celebrates Closing of Business Combination with Nasdaq Bell Ringing

Abpro Statement on the Departure of Former CEO Ian Chan

Abpro Announces Oral Presentation of First Preclinical Data for ABP-102/CT-P72, a Tetravalent Bispecific HER2 x CD3 T-Cell Engager, at AACR Annual Meeting 2025

Abpro and Celltrion Unveil Preclinical Data for ABP-102/CT-P72 at AACR 2025, Showcasing Potential Best-in-Class HER2 x CD3 T-Cell Engager

Comments

Abpro Hldgs

Abpro Hldgs (ABP) Opciones

No option chain data available. Please try again later

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL